The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.
March 31st 2023
A new drug application seeking the approval of fruquintinib for use in the treatment of patients with refractory metastatic colorectal cancer has been submitted to the FDA.
March 29th 2023
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
8th Annual School of Gastrointestinal Oncology® (SOGO®)
05/06/23 8:00 AM – 5:00 PM EDT
Expert Illustrations & Commentaries™: Targeting FGFR2b Overexpression in Advanced Gastric and GEJ Cancers
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Community Practice Connections™: 7th Annual School of Gastrointestinal Oncology®
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
Dr. Shirasu on the Clinical Implications of ctDNA in CRCDecember 20th 2021
Hiromichi Shirasu, MD, discusses the clinical implications of the GALAXY trial as part of the CIRCULATE-Japan project, which is investigating circulating tumor DNA status in patients with resectable colorectal cancer.
Surgical Resectability Remains Crucial in Determining Treatment Strategy in Liver-Only Metastatic CRCDecember 20th 2021
Early identification of patients with liver-only metastatic colorectal cancer who are eligible for resection is crucial to determining their course of treatment and what role modalities like chemotherapy will play in their treatment strategy.
Adavosertib Elicits Efficacy in RAS/TP53+ mCRC With Potential Additive Benefit in Left-Sided TumorsDecember 16th 2021
The WEE1 inhibitor adavosertib improved progression-free survival with a tolerable safety profile compared with active monitoring in patients with RAS/TP53-mutated metastatic colorectal cancer.
ESMO 2021 Updates in Gastric Cancer and Colorectal CancerDecember 6th 2021
Sam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
Dr. Raghav on Treatment Considerations With Regorafenib and TAS-102 in CRCDecember 3rd 2021
Kanwal Raghav, MBBS, MD, discusses the safety profiles of regorafenib and trifluridine/tipiracil, and selecting between the agents for the treatment of patients with colorectal cancer.
Tanios S. Bekaii-Saab, MD, Gerald Prager, MD, and Chiara Cremolini, MD, PhD, provide insight on the treatment landscape and international screening guidelines of colorectal cancer.
CTLA-4 Inhibitor AGEN1181 Shows Early Activity in Heavily Pretreated Advanced Solid Tumors
AGEN1181, a next-generation CTLA-4 inhibitor, exhibited clinical activity both as a monotherapy and in combination with balstilimab in heavily pretreated patients with advanced solid tumors.
Up-front Surgery, Biologics Do Not Improve Survival in Resectable CRC With Liver Metastases
Chemotherapy has demonstrated mixed findings in patients with resectable colorectal hepatic metastases, and long-term data suggest incorporating it into treatment algorithms have little impact on overall survival.
Nivolumab Plus Low-Dose Ipilimumab Provides Robust, Durable Clinical Benefit in Frontline MSI-H/dMMR mCRCNovember 10th 2021
The combination of nivolumab and low-dose ipilimumab resulted in a deep and durable clinical benefit when used in the first-line treatment of patients with microsatellite instability–high and mismatch repair deficient metastatic colorectal cancer.
Targeted Therapies Make Major Strides in mCRC ManagementNovember 7th 2021
The treatment algorithm in metastatic colorectal cancer has gone from accounting only for the sidedness of the primary tumor, performance status, volume of disease, and potential resectability to also include the genetics of the tumor, particularly for patients in need of second-line therapy.
FORTE Trial Set to Examine Optimal Colonoscopy Frequency for CRC PreventionOctober 27th 2021
The randomized FORTE/NRG-CC005 trial, which is evaluating the frequency of surveillance colonoscopy in individuals with a first-time presentation and removal of 1 to 2 small, benign polyps, has been launched.
TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRCOctober 22nd 2021
The frontline combination of trifluridine/tipiracil and bevacizumab was not found to result in a significant improvement in progression-free survival over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial.